Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Samuel A. Korman"'
Autor:
Bram Slütter, Jared S. Bee, Samuel A. Korman, Wim Jiskoot, Mark A. Schenerman, Yuling Wu, Grzegorz Kijanka
Publikováno v:
Journal of Pharmaceutical Sciences
Journal of Pharmaceutical Sciences, 109(1), 730-738
Journal of Pharmaceutical Sciences, 109(1), 730-738
The presence of protein aggregates is commonly believed to be an important risk factor for immunogenicity of therapeutic proteins. Among all types of aggregates, dimers are relatively abundant in most commercialized monoclonal antibody (mAb) products
Autor:
Samuel A. Korman, Yang Jiao, Dengfeng Liu, Niluka De Mel, Mingyan Cao, James Howard, Christopher Thompson, Michaela Wendeler, Conner Parthemore
Publikováno v:
mAbs
Site-specific antibody-drug conjugates (ADCs) are designed to overcome the heterogeneity observed with first-generation ADCs that use random conjugation to surface-exposed lysine residues or conjugation to interchain disulfide bonds. Despite signific
Autor:
Yuling Wu, Lorin Roskos, Wim Jiskoot, Grzegorz Kijanka, Bram Slütter, Jared S. Bee, Mark A. Schenerman, Samuel A. Korman
Publikováno v:
Journal of Pharmaceutical Sciences, 107(11), 2874-2859
Journal of Pharmaceutical Sciences
Journal of Pharmaceutical Sciences
Protein aggregates are one of several risk factors for undesired immunogenicity of biopharmaceuticals. However, it remains unclear which features determine whether aggregates will trigger an unwanted immune response. The aim of this study was to dete
Autor:
Kuldip Sra, Flaviu Gruia, Sonia Dragulin-Otto, Samuel A. Korman, Jared S. Bee, Richard L. Remmele, Arun Parupudi
Publikováno v:
Journal of virological methods. 247
Antigenic drift of the influenza A virus requires that vaccine production is targeted to the strains circulating each year. Live-attenuated influenza A vaccine manufacturing is used to produce intact virions with the surface antigens of the circulati